Table 3.
Multivariate analysis of 5-year overall survival and 5-year disease-free survival in metaplastic breast cancer
| |
5-year OS |
|
|
5-year DFS |
|
|
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| Pathological tumor stage (>T3) |
3.224 |
1.32 to 7.89 |
0.010 |
2.962 |
1.19 to 7.39 |
0.020 |
| Pathological nodal stage (positive) |
3.170 |
1.31 to 7.67 |
0.010 |
1.594 |
1.08 to 2.35 |
0.018 |
| Histological grade (3) |
0.945 |
0.24 to 3.70 |
0.935 |
1.066 |
0.28 to 4.07 |
0.925 |
| P53 (≥25%) |
3.274 |
0.40 to 26.72 |
0.268 |
3.413 |
0.43 to 27.38 |
0.248 |
| Ki-67 (≥14%) |
2.926 |
1.08 to 7.96 |
0.035 |
2.719 |
1.00 to 7.41 |
0.049 |
| Hormone therapy (yes) |
0.290 |
0.06 to 1.42 |
0.126 |
0.341 |
0.07 to 1.68 |
0.185 |
| Subtypes of MBC (SPC) | 1.388 | 0.54 to 3.59 | 0.499 | — | — | — |
MBC, metaplastic breast cancer;SPC, adenocarcinoma with spindle cell differentiation.